SIMILAR PATTERNS OF AMINO ACIDS FOR 1ETR_H_MITH1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1a0j	TRYPSIN (Salmo salar)	PF00089 (Trypsin)	8	HIS A 57 LEU A 99 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	SO4 A 248 (-3.9A) None BEN A 246 (-3.0A) SO4 A 248 ( 2.5A) None None BEN A 246 ( 3.9A) BEN A 246 (-3.3A)	0.56A	1etrH-1a0jA: 33.8	1etrH-1a0jA: 36.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1a5i	PLASMINOGEN ACTIVATOR (Desmodus rotundus)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	0GJ A 245 (-2.7A) 0GJ A 245 (-3.1A) 0GJ A 245 (-1.4A) None 0GJ A 245 (-3.5A) 0GJ A 245 ( 4.2A)	0.68A	1etrH-1a5iA: 32.8	1etrH-1a5iA: 33.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1afq	BOVINE GAMMA-CHYMOTRYPSIN (Bos taurus)	PF00089 (Trypsin)	5	SER C 195 VAL C 213 TRP C 215 GLY C 216 GLY C 226	0FG C 301 ( 3.0A) None None 0FG C 301 (-3.4A) 0FG C 301 ( 4.4A)	0.43A	1etrH-1afqC: 8.5	1etrH-1afqC: 20.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1bqy	PLASMINOGEN ACTIVATOR (Trimeresurus stejnegeri)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	0GJ A 1 ( 2.7A) 0GJ A 1 (-3.1A) 0GJ A 1 ( 1.4A) None None 0GJ A 1 (-3.5A) 0GJ A 1 ( 4.3A)	0.61A	1etrH-1bqyA: 32.2	1etrH-1bqyA: 32.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1bru	ELASTASE (Sus scrofa)	PF00089 (Trypsin)	5	HIS P 57 LEU P 99 SER P 195 VAL P 213 GLY P 216	1NB P 1 (-3.9A) None 1NB P 1 ( 1.2A) None 1NB P 1 ( 4.4A)	0.77A	1etrH-1bruP: 34.5	1etrH-1bruP: 36.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1dlk	THROMBIN HEAVY CHAIN (Bos taurus)	PF00089 (Trypsin)	6	HIS B 57 SER B 195 VAL B 213 TRP B 215 GLY B 216 GLY B 226	None	0.60A	1etrH-1dlkB: 34.6	1etrH-1dlkB: 36.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1ekb	ENTEROPEPTIDASE (Bos taurus)	PF00089 (Trypsin)	5	HIS B 57 ASP B 189 SER B 195 GLY B 216 GLY B 226	None	0.67A	1etrH-1ekbB: 35.6	1etrH-1ekbB: 35.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1elv	COMPLEMENT C1S COMPONENT (Homo sapiens)	PF00084 (Sushi) PF00089 (Trypsin)	7	HIS A 460 ASP A 611 SER A 617 VAL A 638 TRP A 640 GLY A 641 GLY A 648	SO4 A2001 ( 3.9A) None SO4 A2001 ( 2.7A) None None None None	0.63A	1etrH-1elvA: 30.8	1etrH-1elvA: 28.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ept	PORCINE E-TRYPSIN (Sus scrofa)	PF00089 (Trypsin)	8	HIS A 57 LEU B 99 ASP C 189 SER C 195 VAL C 213 TRP C 215 GLY C 216 GLY C 226	None	0.51A	1etrH-1eptA: 2.2	1etrH-1eptA: 10.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1euf	DUODENASE (Bos taurus)	PF00089 (Trypsin)	5	HIS A 57 LEU A 99 SER A 195 VAL A 213 GLY A 216	None	0.63A	1etrH-1eufA: 32.6	1etrH-1eufA: 33.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.60A	1etrH-1fiwA: 34.7	1etrH-1fiwA: 34.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) None PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.54A	1etrH-1fizA: 34.1	1etrH-1fizA: 35.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1fxy	COAGULATION FACTOR XA-TRYPSIN CHIMERA (Homo sapiens)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	0G6 A 1 (-2.7A) 0G6 A 1 (-2.8A) 0G6 A 1 (-1.4A) None None 0G6 A 1 (-3.9A) 0G6 A 1 (-3.3A)	0.67A	1etrH-1fxyA: 32.6	1etrH-1fxyA: 38.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1gpz	COMPLEMENT C1R COMPONENT (Homo sapiens)	PF00084 (Sushi) PF00089 (Trypsin)	5	HIS A 485 SER A 637 VAL A 657 GLY A 660 GLY A 668	None	0.83A	1etrH-1gpzA: 27.2	1etrH-1gpzA: 24.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1gvl	KALLIKREIN 6 (Homo sapiens)	PF00089 (Trypsin)	6	HIS A 57 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None	0.59A	1etrH-1gvlA: 24.8	1etrH-1gvlA: 36.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1h4w	TRYPSIN IVA (Homo sapiens)	PF00089 (Trypsin)	8	HIS A 57 LEU A 99 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None None BEN A 250 (-2.9A) BEN A 250 (-3.6A) None None BEN A 250 (-3.9A) BEN A 250 (-3.3A)	0.45A	1etrH-1h4wA: 34.1	1etrH-1h4wA: 37.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1h9h	TRYPSIN (Sus scrofa)	PF00089 (Trypsin)	8	HIS E 57 LEU E 99 ASP E 189 SER E 195 VAL E 213 TRP E 215 GLY E 216 GLY E 226	None	0.59A	1etrH-1h9hE: 33.8	1etrH-1h9hE: 38.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1id5	THROMBIN (Bos taurus)	PF00089 (Trypsin)	7	HIS H 57 ASP H 189 SER H 195 VAL H 213 TRP H 215 GLY H 216 GLY H 226	None	0.69A	1etrH-1id5H: 43.2	1etrH-1id5H: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1id5	THROMBIN (Bos taurus)	PF00089 (Trypsin)	6	LEU H 99 ASP H 189 SER H 195 VAL H 213 GLY H 216 GLY H 226	None	0.94A	1etrH-1id5H: 43.2	1etrH-1id5H: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1j17	TRYPSIN II, ANIONIC (Rattus norvegicus)	PF00089 (Trypsin)	7	HIS T 57 ASP T 189 SER T 195 VAL T 213 TRP T 215 GLY T 216 GLY T 226	SO4 T 600 (-3.8A) ZEN T 1 ( 3.8A) SO4 T 600 ( 2.6A) ZEN T 1 (-4.1A) ZEN T 1 (-3.4A) ZEN T 1 (-3.7A) ZEN T 1 (-3.7A)	0.49A	1etrH-1j17T: 34.4	1etrH-1j17T: 38.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kig	FACTOR XA (Bos taurus)	PF00089 (Trypsin)	7	HIS H 57 ASP H 189 SER H 195 VAL H 213 TRP H 215 GLY H 216 GLY H 226	None	0.58A	1etrH-1kigH: 34.5	1etrH-1kigH: 40.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1lt3	HEAT-LABILE ENTEROTOXIN (Escherichia coli)	PF01375 (Enterotoxin_a)	5	TYR A 86 TRP A 127 LEU A 22 GLU A 144 GLY A 20	None	0.96A	1etrH-1lt3A: undetectable	1etrH-1lt3A: 19.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1mbq	TRYPSIN (Oncorhynchus keta)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None BEN A1222 (-2.9A) BEN A1222 (-3.5A) None None BEN A1222 (-3.9A) BEN A1222 (-3.4A)	0.42A	1etrH-1mbqA: 33.6	1etrH-1mbqA: 38.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1mkx	PRETHROMBIN-2 (Bos taurus)	PF00089 (Trypsin) PF09396 (Thrombin_light)	8	HIS K 57 TYR K 60 TRP K 60 LEU K 99 SER K 195 TRP K 215 GLY K 216 GLY K 226	None	0.97A	1etrH-1mkxK: 37.1	1etrH-1mkxK: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1mkx	PRETHROMBIN-2 (Bos taurus)	PF00089 (Trypsin) PF09396 (Thrombin_light)	8	HIS K 57 TYR K 60 TRP K 60 LEU K 99 SER K 195 VAL K 213 TRP K 215 GLY K 226	None	0.62A	1etrH-1mkxK: 37.1	1etrH-1mkxK: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1npm	NEUROPSIN (Mus musculus)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None	0.65A	1etrH-1npmA: 33.1	1etrH-1npmA: 34.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1o5f	SERINE PROTEASE HEPSIN (Homo sapiens)	PF00089 (Trypsin)	7	HIS H 57 ASP H 189 SER H 195 VAL H 213 TRP H 215 GLY H 216 GLY H 226	CR9 H 256 (-3.9A) CR9 H 256 (-2.4A) CR9 H 256 (-1.5A) CR9 H 256 (-4.3A) None CR9 H 256 ( 3.8A) CR9 H 256 (-3.0A)	0.56A	1etrH-1o5fH: 35.0	1etrH-1o5fH: 39.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1op2	VENOM SERINE PROTEINASE (Deinagkistrodon acutus)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 VAL A 213 GLY A 216 GLY A 226	None	0.57A	1etrH-1op2A: 31.2	1etrH-1op2A: 33.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1orf	GRANZYME A (Homo sapiens)	PF00089 (Trypsin)	5	HIS A 57 ASP A 189 SER A 195 GLY A 216 GLY A 226	0G6 A 1 (-2.7A) 0G6 A 1 (-2.9A) 0G6 A 1 (-1.3A) 0G6 A 1 (-3.3A) 0G6 A 1 (-3.5A)	0.65A	1etrH-1orfA: 31.3	1etrH-1orfA: 30.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1pfx	FACTOR IXA (Sus scrofa)	PF00089 (Trypsin)	6	HIS C 57 ASP C 189 SER C 195 TRP C 215 GLY C 216 GLY C 226	0G6 C 301 (-2.5A) 0G6 C 301 (-3.0A) 0G6 C 301 (-1.4A) None 0G6 C 301 (-3.2A) 0G6 C 301 ( 3.5A)	0.71A	1etrH-1pfxC: 33.0	1etrH-1pfxC: 40.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1pq5	TRYPSIN (Fusarium oxysporum)	PF00089 (Trypsin)	7	HIS A 56 ASP A 189 SER A 195 VAL A 210 TRP A 212 GLY A 213 GLY A 223	ARG A 703 (-4.3A) ARG A 703 (-2.0A) ARG A 703 (-2.3A) ARG A 703 (-4.5A) None ARG A 703 ( 3.7A) ARG A 703 (-2.6A)	0.54A	1etrH-1pq5A: 32.5	1etrH-1pq5A: 35.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q3x	MANNAN-BINDING LECTIN SERINE PROTEASE 2 (Homo sapiens)	PF00084 (Sushi) PF00089 (Trypsin)	7	HIS A 483 ASP A 627 SER A 633 VAL A 653 TRP A 655 GLY A 656 GLY A 667	None NA A 800 ( 4.6A) GOL A 701 (-3.0A) GOL A 701 (-4.9A) None GOL A 701 ( 4.1A) GOL A 701 ( 4.0A)	0.44A	1etrH-1q3xA: 34.4	1etrH-1q3xA: 27.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1sgf	NERVE GROWTH FACTOR (Mus musculus)	PF00089 (Trypsin)	6	HIS G 57 ASP G 189 SER G 195 TRP G 215 GLY G 216 GLY G 226	None	0.70A	1etrH-1sgfG: 32.2	1etrH-1sgfG: 32.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1spj	KALLIKREIN 1 (Homo sapiens)	PF00089 (Trypsin)	5	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216	None	0.65A	1etrH-1spjA: 32.9	1etrH-1spjA: 31.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1ym0	FIBRINOTIC ENZYME COMPONENT B (Eisenia fetida)	PF00089 (Trypsin)	8	HIS A 57 LEU A 99 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None	0.57A	1etrH-1ym0A: 35.7	1etrH-1ym0A: 33.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zjk	MANNAN-BINDING LECTIN SERINE PROTEASE 2 (Homo sapiens)	PF00084 (Sushi) PF00089 (Trypsin)	6	HIS A 483 SER A 633 VAL A 653 TRP A 655 GLY A 656 GLY A 667	None	0.68A	1etrH-1zjkA: 31.2	1etrH-1zjkA: 23.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1zlr	COAGULATION FACTOR XI (Homo sapiens)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	368 A 901 (-4.0A) 368 A 901 (-2.8A) 368 A 901 (-1.4A) None 368 A 901 (-3.6A) 368 A 901 (-3.5A)	0.43A	1etrH-1zlrA: 34.8	1etrH-1zlrA: 37.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2aip	PROTEIN C ACTIVATOR (Agkistrodon contortrix)	PF00089 (Trypsin)	5	HIS A 57 ASP A 189 SER A 195 GLY A 216 GLY A 226	SO4 A 301 (-3.8A) None SO4 A 301 (-2.8A) None None	0.79A	1etrH-2aipA: 30.4	1etrH-2aipA: 31.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2b6n	PROTEINASE K (Serratia sp. GF96)	PF00082 (Peptidase_S8)	5	TYR A 213 TRP A 212 VAL A 95 GLY A 100 GLY A 102	None	0.96A	1etrH-2b6nA: undetectable	1etrH-2b6nA: 19.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ecr	FLAVIN REDUCTASE COMPONENT (HPAC) OF 4-HYDROXYPHENYLACETA TE 3-MONOOXYGENASE (Thermus thermophilus)	PF01613 (Flavin_Reduct)	5	LEU A 70 GLU A 92 VAL A 102 GLY A 98 GLY A 129	None	0.93A	1etrH-2ecrA: undetectable	1etrH-2ecrA: 21.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2eek	TRYPSIN-1 (Gadus morhua)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None BEN A 301 (-2.7A) BEN A 301 (-3.4A) None None BEN A 301 ( 3.8A) BEN A 301 (-3.2A)	0.43A	1etrH-2eekA: 33.0	1etrH-2eekA: 38.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ei8	COAGULATION FACTOR X, HEAVY CHAIN (Homo sapiens)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None DT8 A 700 (-3.5A) DT8 A 700 ( 3.9A) DT8 A 700 ( 4.1A) DT8 A 700 (-3.9A) DT8 A 700 (-3.5A) DT8 A 700 (-3.5A)	0.60A	1etrH-2ei8A: 35.3	1etrH-2ei8A: 40.61
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2f91	HEPATOPANCREAS TRYPSIN (Astacus leptodactylus)	PF00089 (Trypsin)	8	HIS A 57 LEU A 99 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 227	None	0.50A	1etrH-2f91A: 34.4	1etrH-2f91A: 37.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jet	CHYMOTRYPSINOGEN B CHAIN B CHYMOTRYPSINOGEN B CHAIN C (Rattus norvegicus)	PF00089 (Trypsin)	6	HIS B 57 SER C 195 VAL C 213 TRP C 215 GLY C 216 GLY C 226	None	0.69A	1etrH-2jetB: 13.6	1etrH-2jetB: 26.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2odp	COMPLEMENT C2 (Homo sapiens)	PF00089 (Trypsin) PF00092 (VWA)	5	HIS A 487 SER A 659 VAL A 677 TRP A 679 GLY A 680	None	0.59A	1etrH-2odpA: 23.0	1etrH-2odpA: 19.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2oq5	TRANSMEMBRANE PROTEASE, SERINE 11E (Homo sapiens)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None BEN A 245 (-3.0A) BEN A 245 (-3.3A) None None BEN A 245 ( 3.8A) BEN A 245 (-3.4A)	0.45A	1etrH-2oq5A: 34.6	1etrH-2oq5A: 35.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2pka	KALLIKREIN A (Sus scrofa)	PF00089 (Trypsin)	5	HIS A 57 ASP B 189 SER B 195 TRP B 215 GLY B 216	None BEN B 1 (-3.0A) BEN B 1 ( 4.0A) None BEN B 1 (-3.5A)	0.51A	1etrH-2pkaA: 6.9	1etrH-2pkaA: 16.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2pks	THROMBIN HEAVY CHAIN FRAGMENT (Homo sapiens)	PF00089 (Trypsin)	7	ASP C 229 GLU C 232 SER C 235 VAL C 255 TRP C 257 GLY C 258 GLY C 268	G44 C 101 (-2.6A) None G44 C 101 (-3.5A) None G44 C 101 (-4.1A) G44 C 101 (-3.3A) G44 C 101 (-3.0A)	0.65A	1etrH-2pksC: 12.1	1etrH-2pksC: 38.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psy	KALLIKREIN-5 (Homo sapiens)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None	0.71A	1etrH-2psyA: 33.5	1etrH-2psyA: 34.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qy0	COMPLEMENT C1R SUBCOMPONENT (Homo sapiens)	PF00089 (Trypsin)	7	HIS B 485 ASP B 631 SER B 637 VAL B 657 TRP B 659 GLY B 660 GLY B 668	None	0.47A	1etrH-2qy0B: 32.8	1etrH-2qy0B: 38.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r0l	HEPATOCYTE GROWTH FACTOR ACTIVATOR (Homo sapiens)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None	0.46A	1etrH-2r0lA: 34.7	1etrH-2r0lA: 32.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2w	PLASMINOGEN ACTIVATOR, UROKINASE (Homo sapiens)	PF00089 (Trypsin)	6	HIS U 57 ASP U 189 VAL U 213 TRP U 215 GLY U 216 GLY U 226	4PG U 300 (-3.9A) 4PG U 300 (-2.8A) None None 4PG U 300 (-3.3A) 4PG U 300 (-3.2A)	0.42A	1etrH-2r2wU: 35.1	1etrH-2r2wU: 31.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2w	PLASMINOGEN ACTIVATOR, UROKINASE (Homo sapiens)	PF00089 (Trypsin)	6	HIS U 57 SER U 195 VAL U 213 TRP U 215 GLY U 216 GLY U 226	4PG U 300 (-3.9A) 4PG U 300 (-3.5A) None None 4PG U 300 (-3.3A) 4PG U 300 (-3.2A)	0.51A	1etrH-2r2wU: 35.1	1etrH-2r2wU: 31.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2wpm	COAGULATION FACTOR IXA HEAVY CHAIN (Homo sapiens)	PF00089 (Trypsin)	6	HIS S 57 ASP S 189 SER S 195 TRP S 215 GLY S 216 GLY S 226	None	0.72A	1etrH-2wpmS: 34.5	1etrH-2wpmS: 39.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zec	TRYPTASE BETA 2 (Homo sapiens)	PF00089 (Trypsin)	7	HIS A 59 ASP A 203 SER A 209 VAL A 227 TRP A 229 GLY A 230 GLY A 240	None 11N A 1 (-2.6A) 11N A 1 (-3.3A) None None 11N A 1 (-3.9A) 11N A 1 (-3.6A)	0.55A	1etrH-2zecA: 33.3	1etrH-2zecA: 36.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3beu	TRYPSIN (Streptomyces griseus)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	SO4 A 246 ( 3.8A) BEN A 247 (-3.0A) SO4 A 246 ( 2.5A) None None BEN A 247 (-3.7A) BEN A 247 (-3.5A)	0.49A	1etrH-3beuA: 31.3	1etrH-3beuA: 35.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3f6u	VITAMIN K-DEPENDENT PROTEIN C HEAVY CHAIN (Homo sapiens)	PF00089 (Trypsin)	7	ASP H 189 GLU H 192 SER H 195 VAL H 213 TRP H 215 GLY H 216 GLY H 226	0G6 H 1 (-2.8A) 0G6 H 1 ( 4.0A) 0G6 H 1 (-1.8A) None 0G6 H 1 (-4.1A) 0G6 H 1 (-3.8A) 0G6 H 1 ( 3.9A)	0.66A	1etrH-3f6uH: 35.2	1etrH-3f6uH: 41.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3f6u	VITAMIN K-DEPENDENT PROTEIN C HEAVY CHAIN (Homo sapiens)	PF00089 (Trypsin)	7	HIS H 57 ASP H 189 SER H 195 VAL H 213 TRP H 215 GLY H 216 GLY H 226	0G6 H 1 (-3.2A) 0G6 H 1 (-2.8A) 0G6 H 1 (-1.8A) None 0G6 H 1 (-4.1A) 0G6 H 1 (-3.8A) 0G6 H 1 ( 3.9A)	0.67A	1etrH-3f6uH: 35.2	1etrH-3f6uH: 41.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3gov	MASP-1 (Homo sapiens)	PF00089 (Trypsin)	7	HIS B 490 ASP B 640 SER B 646 VAL B 666 TRP B 668 GLY B 669 GLY B 679	None	0.55A	1etrH-3govB: 36.0	1etrH-3govB: 36.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3gym	PROSTASIN (Homo sapiens)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None	0.66A	1etrH-3gymA: 33.8	1etrH-3gymA: 37.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3nxp	PRETHROMBIN-1 (Homo sapiens)	PF00051 (Kringle) PF00089 (Trypsin) PF09396 (Thrombin_light)	5	HIS A 457 TYR A 460 LEU A 499 VAL A 613 GLY A 626	None	0.57A	1etrH-3nxpA: 29.6	1etrH-3nxpA: 87.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3r3g	THROMBIN HEAVY CHAIN (Homo sapiens)	PF00089 (Trypsin)	10	HIS B 57 TYR B 60 LEU B 99 ASP B 189 GLU B 192 SER B 195 VAL B 213 TRP B 215 GLY B 216 GLY B 226	None	0.78A	1etrH-3r3gB: 43.5	1etrH-3r3gB: 88.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3r3g	THROMBIN HEAVY CHAIN (Homo sapiens)	PF00089 (Trypsin)	6	TYR B 60 TRP B 60 LEU B 99 ASP B 189 GLY B 216 GLY B 226	None	0.79A	1etrH-3r3gB: 43.5	1etrH-3r3gB: 88.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3rip	GAMMA-TUBULIN COMPLEX COMPONENT 4 (Homo sapiens)	PF04130 (Spc97_Spc98)	5	LEU A 197 GLU A 304 SER A 188 GLY A 194 GLY A 280	None	0.85A	1etrH-3ripA: undetectable	1etrH-3ripA: 17.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3s69	THROMBIN-LIKE ENZYME DEFIBRASE (Gloydius saxatilis)	PF00089 (Trypsin)	6	HIS A 56 ASP A 189 SER A 195 VAL A 209 GLY A 212 GLY A 223	None	0.53A	1etrH-3s69A: 31.3	1etrH-3s69A: 32.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3w94	ENTEROPEPTIDASE-1 (Oryzias latipes)	PF00089 (Trypsin)	5	HIS A 836 ASP A 973 SER A 979 GLY A1000 GLY A1010	None	0.54A	1etrH-3w94A: 36.1	1etrH-3w94A: 35.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4bxw	FACTOR XA (Pseudonaja textilis)	PF00089 (Trypsin) PF14670 (FXa_inhibition)	6	HIS A 211 ASP A 356 SER A 362 VAL A 380 GLY A 383 GLY A 393	0GJ A1411 (-2.8A) 0GJ A1411 (-2.7A) 0GJ A1411 (-1.4A) None 0GJ A1411 (-3.7A) 0GJ A1411 (-3.3A)	0.69A	1etrH-4bxwA: 32.9	1etrH-4bxwA: 38.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dgj	ENTEROPEPTIDASE CATALYTIC LIGHT CHAIN (Homo sapiens)	PF00089 (Trypsin)	5	HIS A 41 ASP A 181 SER A 187 GLY A 208 GLY A 218	None	0.72A	1etrH-4dgjA: 36.3	1etrH-4dgjA: 35.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4dzt	AQUALYSIN-1 (Thermus aquaticus)	PF00082 (Peptidase_S8)	5	TYR A 209 TRP A 208 VAL A 96 GLY A 101 GLY A 103	None	0.93A	1etrH-4dztA: undetectable	1etrH-4dztA: 18.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4e7n	SNAKE-VENOM THROMBIN-LIKE ENZYME (Gloydius halys)	PF00089 (Trypsin)	5	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216	None	0.62A	1etrH-4e7nA: 31.0	1etrH-4e7nA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fxg	MANNAN-BINDING LECTIN SERINE PROTEASE 2 B CHAIN (Homo sapiens)	PF00089 (Trypsin)	6	HIS H 483 ASP H 627 VAL H 653 TRP H 655 GLY H 656 GLY H 667	None	0.55A	1etrH-4fxgH: 34.7	1etrH-4fxgH: 34.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gso	THROMBIN-LIKE ENZYME BJUSSUSP-1 (Bothrops jararacussu)	PF00089 (Trypsin)	5	ASP A 172 SER A 178 VAL A 192 GLY A 195 GLY A 206	None	0.62A	1etrH-4gsoA: undetectable	1etrH-4gsoA: 34.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4h4f	CHYMOTRYPSIN-C (Homo sapiens)	PF00089 (Trypsin)	5	HIS A 57 LEU A 99 SER A 195 VAL A 213 GLY A 216	None	0.59A	1etrH-4h4fA: 34.4	1etrH-4h4fA: 34.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzh	PROTHROMBIN (Homo sapiens)	PF00051 (Kringle) PF00089 (Trypsin) PF09396 (Thrombin_light)	6	HIS A 363 TYR A 367 TRP A 370 LEU A 416 VAL A 545 GLY A 558	None	0.93A	1etrH-4hzhA: 29.8	1etrH-4hzhA: 86.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzh	PROTHROMBIN (Homo sapiens)	PF00051 (Kringle) PF00089 (Trypsin) PF09396 (Thrombin_light)	6	HIS A 363 TYR A 367 TRP A 370 VAL A 545 GLY A 548 GLY A 558	None	1.29A	1etrH-4hzhA: 29.8	1etrH-4hzhA: 86.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4iw4	MANNAN-BINDING LECTIN SERINE PROTEASE 3 (Homo sapiens)	PF00089 (Trypsin)	7	HIS E 478 ASP E 639 SER E 645 VAL E 665 TRP E 667 GLY E 668 GLY E 680	None	0.70A	1etrH-4iw4E: 32.7	1etrH-4iw4E: 35.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k8y	KALLIKREIN-4 (Homo sapiens)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 VAL A 213 GLY A 216 GLY A 226	None	0.57A	1etrH-4k8yA: 32.5	1etrH-4k8yA: 32.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k8y	KALLIKREIN-4 (Homo sapiens)	PF00089 (Trypsin)	6	LEU A 99 ASP A 189 SER A 195 VAL A 213 GLY A 216 GLY A 226	None	0.86A	1etrH-4k8yA: 32.5	1etrH-4k8yA: 32.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4kkd	MANNAN-BINDING LECTIN SERINE PROTEASE 1 (Homo sapiens)	PF00084 (Sushi) PF00089 (Trypsin)	5	HIS A 497 VAL A 684 TRP A 686 GLY A 687 GLY A 699	None	0.54A	1etrH-4kkdA: 29.5	1etrH-4kkdA: 24.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lk4	VESB PROTEASE (Vibrio cholerae)	PF00089 (Trypsin)	6	HIS A 78 LEU A 122 VAL A 237 TRP A 239 GLY A 240 GLY A 251	None	0.64A	1etrH-4lk4A: 27.3	1etrH-4lk4A: 27.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4m7g	TRYPSIN-LIKE PROTEASE (Saccharopolyspora erythraea)	PF00089 (Trypsin)	6	HIS A 42 ASP A 173 SER A 179 TRP A 195 GLY A 196 GLY A 206	None	0.43A	1etrH-4m7gA: 32.3	1etrH-4m7gA: 33.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nff	KALLIKREIN-2 (Homo sapiens)	PF00089 (Trypsin)	5	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216	0G6 A 301 (-2.7A) 0G6 A 301 (-3.0A) 0G6 A 301 (-1.4A) 0G6 A 301 (-3.7A) 0G6 A 301 (-3.4A)	0.82A	1etrH-4nffA: 33.4	1etrH-4nffA: 34.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4r0i	SUPPRESSOR OF TUMORIGENICITY 14 PROTEIN (Homo sapiens)	PF00089 (Trypsin)	7	HIS A 57 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	3KM A 900 ( 4.4A) 3KM A 900 (-2.9A) 3KM A 900 (-3.6A) None None 3KM A 900 (-3.4A) 3KM A 900 (-3.2A)	0.50A	1etrH-4r0iA: 36.1	1etrH-4r0iA: 35.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4wwy	TRYPSIN-1 (Homo sapiens)	PF00089 (Trypsin)	8	HIS A 57 LEU A 99 ASP A 189 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None	0.70A	1etrH-4wwyA: 33.9	1etrH-4wwyA: 36.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ylq	COAGULATION FACTOR VII (Homo sapiens)	PF00089 (Trypsin)	7	HIS H 57 ASP H 189 SER H 195 VAL H 213 TRP H 215 GLY H 216 GLY H 226	0Z7 H 501 (-2.6A) 0Z7 H 501 (-2.3A) 0Z7 H 501 (-1.4A) 0Z7 H 501 ( 4.7A) TMA H 508 ( 3.9A) 0Z7 H 501 (-3.4A) 0Z7 H 501 (-3.0A)	0.63A	1etrH-4ylqH: 34.5	1etrH-4ylqH: 36.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5brr	TISSUE-TYPE PLASMINOGEN ACTIVATOR (Homo sapiens)	PF00089 (Trypsin)	5	HIS E 57 ASP E 189 TRP E 215 GLY E 216 GLY E 226	None	0.50A	1etrH-5brrE: 34.9	1etrH-5brrE: 32.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eod	COAGULATION FACTOR XI (Homo sapiens)	PF00024 (PAN_1) PF00089 (Trypsin)	5	HIS A 413 SER A 557 TRP A 577 GLY A 578 GLY A 588	None	0.80A	1etrH-5eodA: 27.5	1etrH-5eodA: 17.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f8z	PLASMA KALLIKREIN LIGHT CHAIN (Homo sapiens)	PF00089 (Trypsin)	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None	0.47A	1etrH-5f8zA: 34.7	1etrH-5f8zA: 39.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gvt	PLASMA KALLIKREIN (Mus musculus)	no annotation	5	HIS A 57 ASP A 189 SER A 195 GLY A 216 GLY A 226	None	0.65A	1etrH-5gvtA: 34.6	1etrH-5gvtA: 18.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ms3	KALLIKREIN-8 (Homo sapiens)	no annotation	6	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None	0.58A	1etrH-5ms3A: 32.9	1etrH-5ms3A: 15.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5n1q	METHYL-COENZYME M REDUCTASE III FROM METHANOTHERMOCOCCUS THERMOLITHOTROPHICUS SUBUNIT BETA (Methanothermococcus thermolithotrophicus)	PF02241 (MCR_beta) PF02783 (MCR_beta_N)	5	HIS B 199 TYR B 200 LEU B 178 ASP B 169 GLY B 180	None	0.93A	1etrH-5n1qB: undetectable	1etrH-5n1qB: 21.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5n28	METHYL-COENZYME M REDUCTASE, BETA SUBUNIT (Methanotorris formicicus)	PF02241 (MCR_beta) PF02783 (MCR_beta_N)	5	HIS B 199 TYR B 200 LEU B 178 ASP B 169 GLY B 180	None	0.88A	1etrH-5n28B: undetectable	1etrH-5n28B: 22.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o32	COMPLEMENT FACTOR I (Homo sapiens)	PF00089 (Trypsin)	5	ASP I 519 VAL I 544 TRP I 546 GLY I 547 GLY I 557	None	0.86A	1etrH-5o32I: 31.0	1etrH-5o32I: 34.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o32	COMPLEMENT FACTOR I (Homo sapiens)	PF00089 (Trypsin)	5	HIS I 380 VAL I 544 TRP I 546 GLY I 547 GLY I 557	None	0.61A	1etrH-5o32I: 31.0	1etrH-5o32I: 34.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5to3	PROTHROMBIN,THROMBOM ODULIN (Homo sapiens)	PF00089 (Trypsin) PF09064 (Tme5_EGF_like)	8	HIS B 58 TYR B 62 LEU B 111 ASP B 214 SER B 220 VAL B 240 GLY B 243 GLY B 253	0G6 B 501 (-2.5A) 0G6 B 501 (-3.7A) 0G6 B 501 ( 3.8A) 0G6 B 501 (-2.9A) 0G6 B 501 (-1.3A) None 0G6 B 501 (-3.7A) 0G6 B 501 (-3.6A)	0.60A	1etrH-5to3B: 44.1	1etrH-5to3B: 79.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5to3	PROTHROMBIN,THROMBOM ODULIN (Homo sapiens)	PF00089 (Trypsin) PF09064 (Tme5_EGF_like)	6	TYR B 62 TRP B 65 LEU B 111 ASP B 214 GLY B 243 GLY B 253	0G6 B 501 (-3.7A) 0G6 B 501 (-4.8A) 0G6 B 501 ( 3.8A) 0G6 B 501 (-2.9A) 0G6 B 501 (-3.7A) 0G6 B 501 (-3.6A)	0.73A	1etrH-5to3B: 44.1	1etrH-5to3B: 79.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ubm	COMPLEMENT C1S SUBCOMPONENT (Homo sapiens)	no annotation	7	HIS A 475 ASP A 626 SER A 632 VAL A 653 TRP A 655 GLY A 656 GLY A 663	None	0.71A	1etrH-5ubmA: 31.3	1etrH-5ubmA: 34.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xrf	SNAKE VENOM SERINE PROTEASE DA-36 (Deinagkistrodon acutus)	no annotation	6	HIS A 67 ASP A 200 SER A 206 VAL A 220 GLY A 223 GLY A 234	None	0.67A	1etrH-5xrfA: 29.7	1etrH-5xrfA: 13.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5zfh	KALLIKREIN-7 (Mus musculus)	no annotation	6	HIS A 57 SER A 195 VAL A 213 TRP A 215 GLY A 216 GLY A 226	None	0.47A	1etrH-5zfhA: 32.8	1etrH-5zfhA: 17.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b74	COAGULATION FACTOR XII (Homo sapiens)	no annotation	6	HIS B 57 ASP B 189 SER B 195 TRP B 215 GLY B 216 GLY B 226	SO4 B 304 (-3.8A) BEN B 301 (-2.7A) SO4 B 304 ( 2.5A) None BEN B 301 (-3.3A) BEN B 301 (-3.1A)	0.58A	1etrH-6b74B: 34.4	1etrH-6b74B: 15.66

[["1ETR_H_MITH1_1","1a0j","Salmo salar","TRYPSIN","PF00089(Trypsin)",8,"HIS A  57;LEU A  99;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","SO4 A 248 (-3.9A);None;BEN A 246 (-3.0A);SO4 A 248 ( 2.5A);None;None;BEN A 246 ( 3.9A);BEN A 246 (-3.3A)","0.56A","1etrH-1a0jA:33.8","1etrH-1a0jA:36.58"],["1ETR_H_MITH1_1","1a5i","Desmodus rotundus","PLASMINOGEN ACTIVATOR","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","0GJ A 245 (-2.7A);0GJ A 245 (-3.1A);0GJ A 245 (-1.4A);None;0GJ A 245 (-3.5A);0GJ A 245 ( 4.2A)","0.68A","1etrH-1a5iA:32.8","1etrH-1a5iA:33.45"],["1ETR_H_MITH1_1","1afq","Bos taurus","BOVINE GAMMA-CHYMOTRYPSIN","PF00089(Trypsin)",5,"SER C 195;VAL C 213;TRP C 215;GLY C 216;GLY C 226","0FG C 301 ( 3.0A);None;None;0FG C 301 (-3.4A);0FG C 301 ( 4.4A)","0.43A","1etrH-1afqC:8.5","1etrH-1afqC:20.49"],["1ETR_H_MITH1_1","1bqy","Trimeresurus stejnegeri","PLASMINOGEN ACTIVATOR","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","0GJ A   1 ( 2.7A);0GJ A   1 (-3.1A);0GJ A   1 ( 1.4A);None;None;0GJ A   1 (-3.5A);0GJ A   1 ( 4.3A)","0.61A","1etrH-1bqyA:32.2","1etrH-1bqyA:32.08"],["1ETR_H_MITH1_1","1bru","Sus scrofa","ELASTASE","PF00089(Trypsin)",5,"HIS P  57;LEU P  99;SER P 195;VAL P 213;GLY P 216","1NB P   1 (-3.9A);None;1NB P   1 ( 1.2A);None;1NB P   1 ( 4.4A)","0.77A","1etrH-1bruP:34.5","1etrH-1bruP:36.12"],["1ETR_H_MITH1_1","1dlk","Bos taurus","THROMBIN HEAVY CHAIN","PF00089(Trypsin)",6,"HIS B  57;SER B 195;VAL B 213;TRP B 215;GLY B 216;GLY B 226","None","0.60A","1etrH-1dlkB:34.6","1etrH-1dlkB:36.74"],["1ETR_H_MITH1_1","1ekb","Bos taurus","ENTEROPEPTIDASE","PF00089(Trypsin)",5,"HIS B  57;ASP B 189;SER B 195;GLY B 216;GLY B 226","None","0.67A","1etrH-1ekbB:35.6","1etrH-1ekbB:35.25"],["1ETR_H_MITH1_1","1elv","Homo sapiens","COMPLEMENT C1S COMPONENT","PF00084(Sushi);PF00089(Trypsin)",7,"HIS A 460;ASP A 611;SER A 617;VAL A 638;TRP A 640;GLY A 641;GLY A 648","SO4 A2001 ( 3.9A);None;SO4 A2001 ( 2.7A);None;None;None;None","0.63A","1etrH-1elvA:30.8","1etrH-1elvA:28.21"],["1ETR_H_MITH1_1","1ept","Sus scrofa","PORCINE E-TRYPSIN","PF00089(Trypsin)",8,"HIS A  57;LEU B  99;ASP C 189;SER C 195;VAL C 213;TRP C 215;GLY C 216;GLY C 226","None","0.51A","1etrH-1eptA:2.2","1etrH-1eptA:10.99"],["1ETR_H_MITH1_1","1euf","Bos taurus","DUODENASE","PF00089(Trypsin)",5,"HIS A  57;LEU A  99;SER A 195;VAL A 213;GLY A 216","None","0.63A","1etrH-1eufA:32.6","1etrH-1eufA:33.08"],["1ETR_H_MITH1_1","1fiw","Ovis aries","BETA-ACROSIN HEAVY CHAIN","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None;PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.60A","1etrH-1fiwA:34.7","1etrH-1fiwA:34.12"],["1ETR_H_MITH1_1","1fiz","Sus scrofa","BETA-ACROSIN HEAVY CHAIN","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None;PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);None;PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.54A","1etrH-1fizA:34.1","1etrH-1fizA:35.46"],["1ETR_H_MITH1_1","1fxy","Homo sapiens","COAGULATION FACTOR XA-TRYPSIN CHIMERA","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","0G6 A   1 (-2.7A);0G6 A   1 (-2.8A);0G6 A   1 (-1.4A);None;None;0G6 A   1 (-3.9A);0G6 A   1 (-3.3A)","0.67A","1etrH-1fxyA:32.6","1etrH-1fxyA:38.22"],["1ETR_H_MITH1_1","1gpz","Homo sapiens","COMPLEMENT C1R COMPONENT","PF00084(Sushi);PF00089(Trypsin)",5,"HIS A 485;SER A 637;VAL A 657;GLY A 660;GLY A 668","None","0.83A","1etrH-1gpzA:27.2","1etrH-1gpzA:24.64"],["1ETR_H_MITH1_1","1gvl","Homo sapiens","KALLIKREIN 6","PF00089(Trypsin)",6,"HIS A  57;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None","0.59A","1etrH-1gvlA:24.8","1etrH-1gvlA:36.43"],["1ETR_H_MITH1_1","1h4w","Homo sapiens","TRYPSIN IVA","PF00089(Trypsin)",8,"HIS A  57;LEU A  99;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None;None;BEN A 250 (-2.9A);BEN A 250 (-3.6A);None;None;BEN A 250 (-3.9A);BEN A 250 (-3.3A)","0.45A","1etrH-1h4wA:34.1","1etrH-1h4wA:37.45"],["1ETR_H_MITH1_1","1h9h","Sus scrofa","TRYPSIN","PF00089(Trypsin)",8,"HIS E  57;LEU E  99;ASP E 189;SER E 195;VAL E 213;TRP E 215;GLY E 216;GLY E 226","None","0.59A","1etrH-1h9hE:33.8","1etrH-1h9hE:38.52"],["1ETR_H_MITH1_1","1id5","Bos taurus","THROMBIN","PF00089(Trypsin)",7,"HIS H  57;ASP H 189;SER H 195;VAL H 213;TRP H 215;GLY H 216;GLY H 226","None","0.69A","1etrH-1id5H:43.2","1etrH-1id5H:100.00"],["1ETR_H_MITH1_1","1id5","Bos taurus","THROMBIN","PF00089(Trypsin)",6,"LEU H  99;ASP H 189;SER H 195;VAL H 213;GLY H 216;GLY H 226","None","0.94A","1etrH-1id5H:43.2","1etrH-1id5H:100.00"],["1ETR_H_MITH1_1","1j17","Rattus norvegicus","TRYPSIN II, ANIONIC","PF00089(Trypsin)",7,"HIS T  57;ASP T 189;SER T 195;VAL T 213;TRP T 215;GLY T 216;GLY T 226","SO4 T 600 (-3.8A);ZEN T   1 ( 3.8A);SO4 T 600 ( 2.6A);ZEN T   1 (-4.1A);ZEN T   1 (-3.4A);ZEN T   1 (-3.7A);ZEN T   1 (-3.7A)","0.49A","1etrH-1j17T:34.4","1etrH-1j17T:38.55"],["1ETR_H_MITH1_1","1kig","Bos taurus","FACTOR XA","PF00089(Trypsin)",7,"HIS H  57;ASP H 189;SER H 195;VAL H 213;TRP H 215;GLY H 216;GLY H 226","None","0.58A","1etrH-1kigH:34.5","1etrH-1kigH:40.38"],["1ETR_H_MITH1_1","1lt3","Escherichia coli","HEAT-LABILE ENTEROTOXIN","PF01375(Enterotoxin_a)",5,"TYR A  86;TRP A 127;LEU A  22;GLU A 144;GLY A  20","None","0.96A","1etrH-1lt3A:undetectable","1etrH-1lt3A:19.49"],["1ETR_H_MITH1_1","1mbq","Oncorhynchus keta","TRYPSIN","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None;BEN A1222 (-2.9A);BEN A1222 (-3.5A);None;None;BEN A1222 (-3.9A);BEN A1222 (-3.4A)","0.42A","1etrH-1mbqA:33.6","1etrH-1mbqA:38.22"],["1ETR_H_MITH1_1","1mkx","Bos taurus","PRETHROMBIN-2","PF00089(Trypsin);PF09396(Thrombin_light)",8,"HIS K  57;TYR K  60;TRP K  60;LEU K  99;SER K 195;TRP K 215;GLY K 216;GLY K 226","None","0.97A","1etrH-1mkxK:37.1","1etrH-1mkxK:100.00"],["1ETR_H_MITH1_1","1mkx","Bos taurus","PRETHROMBIN-2","PF00089(Trypsin);PF09396(Thrombin_light)",8,"HIS K  57;TYR K  60;TRP K  60;LEU K  99;SER K 195;VAL K 213;TRP K 215;GLY K 226","None","0.62A","1etrH-1mkxK:37.1","1etrH-1mkxK:100.00"],["1ETR_H_MITH1_1","1npm","Mus musculus","NEUROPSIN","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None","0.65A","1etrH-1npmA:33.1","1etrH-1npmA:34.50"],["1ETR_H_MITH1_1","1o5f","Homo sapiens","SERINE PROTEASE HEPSIN","PF00089(Trypsin)",7,"HIS H  57;ASP H 189;SER H 195;VAL H 213;TRP H 215;GLY H 216;GLY H 226","CR9 H 256 (-3.9A);CR9 H 256 (-2.4A);CR9 H 256 (-1.5A);CR9 H 256 (-4.3A);None;CR9 H 256 ( 3.8A);CR9 H 256 (-3.0A)","0.56A","1etrH-1o5fH:35.0","1etrH-1o5fH:39.93"],["1ETR_H_MITH1_1","1op2","Deinagkistrodon acutus","VENOM SERINE PROTEINASE","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;VAL A 213;GLY A 216;GLY A 226","None","0.57A","1etrH-1op2A:31.2","1etrH-1op2A:33.46"],["1ETR_H_MITH1_1","1orf","Homo sapiens","GRANZYME A","PF00089(Trypsin)",5,"HIS A  57;ASP A 189;SER A 195;GLY A 216;GLY A 226","0G6 A   1 (-2.7A);0G6 A   1 (-2.9A);0G6 A   1 (-1.3A);0G6 A   1 (-3.3A);0G6 A   1 (-3.5A)","0.65A","1etrH-1orfA:31.3","1etrH-1orfA:30.34"],["1ETR_H_MITH1_1","1pfx","Sus scrofa","FACTOR IXA","PF00089(Trypsin)",6,"HIS C  57;ASP C 189;SER C 195;TRP C 215;GLY C 216;GLY C 226","0G6 C 301 (-2.5A);0G6 C 301 (-3.0A);0G6 C 301 (-1.4A);None;0G6 C 301 (-3.2A);0G6 C 301 ( 3.5A)","0.71A","1etrH-1pfxC:33.0","1etrH-1pfxC:40.08"],["1ETR_H_MITH1_1","1pq5","Fusarium oxysporum","TRYPSIN","PF00089(Trypsin)",7,"HIS A  56;ASP A 189;SER A 195;VAL A 210;TRP A 212;GLY A 213;GLY A 223","ARG A 703 (-4.3A);ARG A 703 (-2.0A);ARG A 703 (-2.3A);ARG A 703 (-4.5A);None;ARG A 703 ( 3.7A);ARG A 703 (-2.6A)","0.54A","1etrH-1pq5A:32.5","1etrH-1pq5A:35.25"],["1ETR_H_MITH1_1","1q3x","Homo sapiens","MANNAN-BINDING LECTIN SERINE PROTEASE 2","PF00084(Sushi);PF00089(Trypsin)",7,"HIS A 483;ASP A 627;SER A 633;VAL A 653;TRP A 655;GLY A 656;GLY A 667","None; NA A 800 ( 4.6A);GOL A 701 (-3.0A);GOL A 701 (-4.9A);None;GOL A 701 ( 4.1A);GOL A 701 ( 4.0A)","0.44A","1etrH-1q3xA:34.4","1etrH-1q3xA:27.17"],["1ETR_H_MITH1_1","1sgf","Mus musculus","NERVE GROWTH FACTOR","PF00089(Trypsin)",6,"HIS G  57;ASP G 189;SER G 195;TRP G 215;GLY G 216;GLY G 226","None","0.70A","1etrH-1sgfG:32.2","1etrH-1sgfG:32.35"],["1ETR_H_MITH1_1","1spj","Homo sapiens","KALLIKREIN 1","PF00089(Trypsin)",5,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216","None","0.65A","1etrH-1spjA:32.9","1etrH-1spjA:31.44"],["1ETR_H_MITH1_1","1ym0","Eisenia fetida","FIBRINOTIC ENZYME COMPONENT B","PF00089(Trypsin)",8,"HIS A  57;LEU A  99;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None","0.57A","1etrH-1ym0A:35.7","1etrH-1ym0A:33.46"],["1ETR_H_MITH1_1","1zjk","Homo sapiens","MANNAN-BINDING LECTIN SERINE PROTEASE 2","PF00084(Sushi);PF00089(Trypsin)",6,"HIS A 483;SER A 633;VAL A 653;TRP A 655;GLY A 656;GLY A 667","None","0.68A","1etrH-1zjkA:31.2","1etrH-1zjkA:23.90"],["1ETR_H_MITH1_1","1zlr","Homo sapiens","COAGULATION FACTOR XI","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","368 A 901 (-4.0A);368 A 901 (-2.8A);368 A 901 (-1.4A);None;368 A 901 (-3.6A);368 A 901 (-3.5A)","0.43A","1etrH-1zlrA:34.8","1etrH-1zlrA:37.07"],["1ETR_H_MITH1_1","2aip","Agkistrodon contortrix","PROTEIN C ACTIVATOR","PF00089(Trypsin)",5,"HIS A  57;ASP A 189;SER A 195;GLY A 216;GLY A 226","SO4 A 301 (-3.8A);None;SO4 A 301 (-2.8A);None;None","0.79A","1etrH-2aipA:30.4","1etrH-2aipA:31.87"],["1ETR_H_MITH1_1","2b6n","Serratia sp. GF96","PROTEINASE K","PF00082(Peptidase_S8)",5,"TYR A 213;TRP A 212;VAL A  95;GLY A 100;GLY A 102","None","0.96A","1etrH-2b6nA:undetectable","1etrH-2b6nA:19.14"],["1ETR_H_MITH1_1","2ecr","Thermus thermophilus","FLAVIN REDUCTASE COMPONENT (HPAC) OF 4-HYDROXYPHENYLACETATE 3-MONOOXYGENASE","PF01613(Flavin_Reduct)",5,"LEU A  70;GLU A  92;VAL A 102;GLY A  98;GLY A 129","None","0.93A","1etrH-2ecrA:undetectable","1etrH-2ecrA:21.90"],["1ETR_H_MITH1_1","2eek","Gadus morhua","TRYPSIN-1","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None;BEN A 301 (-2.7A);BEN A 301 (-3.4A);None;None;BEN A 301 ( 3.8A);BEN A 301 (-3.2A)","0.43A","1etrH-2eekA:33.0","1etrH-2eekA:38.76"],["1ETR_H_MITH1_1","2ei8","Homo sapiens","COAGULATION FACTOR X, HEAVY CHAIN","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None;DT8 A 700 (-3.5A);DT8 A 700 ( 3.9A);DT8 A 700 ( 4.1A);DT8 A 700 (-3.9A);DT8 A 700 (-3.5A);DT8 A 700 (-3.5A)","0.60A","1etrH-2ei8A:35.3","1etrH-2ei8A:40.61"],["1ETR_H_MITH1_1","2f91","Astacus leptodactylus","HEPATOPANCREAS TRYPSIN","PF00089(Trypsin)",8,"HIS A  57;LEU A  99;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 227","None","0.50A","1etrH-2f91A:34.4","1etrH-2f91A:37.74"],["1ETR_H_MITH1_1","2jet","Rattus norvegicus","CHYMOTRYPSINOGEN B CHAIN B;CHYMOTRYPSINOGEN B CHAIN C","PF00089(Trypsin)",6,"HIS B  57;SER C 195;VAL C 213;TRP C 215;GLY C 216;GLY C 226","None","0.69A","1etrH-2jetB:13.6","1etrH-2jetB:26.58"],["1ETR_H_MITH1_1","2odp","Homo sapiens","COMPLEMENT C2","PF00089(Trypsin);PF00092(VWA)",5,"HIS A 487;SER A 659;VAL A 677;TRP A 679;GLY A 680","None","0.59A","1etrH-2odpA:23.0","1etrH-2odpA:19.32"],["1ETR_H_MITH1_1","2oq5","Homo sapiens","TRANSMEMBRANE PROTEASE, SERINE 11E","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None;BEN A 245 (-3.0A);BEN A 245 (-3.3A);None;None;BEN A 245 ( 3.8A);BEN A 245 (-3.4A)","0.45A","1etrH-2oq5A:34.6","1etrH-2oq5A:35.14"],["1ETR_H_MITH1_1","2pka","Sus scrofa","KALLIKREIN A","PF00089(Trypsin)",5,"HIS A  57;ASP B 189;SER B 195;TRP B 215;GLY B 216","None;BEN B   1 (-3.0A);BEN B   1 ( 4.0A);None;BEN B   1 (-3.5A)","0.51A","1etrH-2pkaA:6.9","1etrH-2pkaA:16.60"],["1ETR_H_MITH1_1","2pks","Homo sapiens","THROMBIN HEAVY CHAIN FRAGMENT","PF00089(Trypsin)",7,"ASP C 229;GLU C 232;SER C 235;VAL C 255;TRP C 257;GLY C 258;GLY C 268","G44 C 101 (-2.6A);None;G44 C 101 (-3.5A);None;G44 C 101 (-4.1A);G44 C 101 (-3.3A);G44 C 101 (-3.0A)","0.65A","1etrH-2pksC:12.1","1etrH-2pksC:38.34"],["1ETR_H_MITH1_1","2psy","Homo sapiens","KALLIKREIN-5","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None","0.71A","1etrH-2psyA:33.5","1etrH-2psyA:34.62"],["1ETR_H_MITH1_1","2qy0","Homo sapiens","COMPLEMENT C1R SUBCOMPONENT","PF00089(Trypsin)",7,"HIS B 485;ASP B 631;SER B 637;VAL B 657;TRP B 659;GLY B 660;GLY B 668","None","0.47A","1etrH-2qy0B:32.8","1etrH-2qy0B:38.49"],["1ETR_H_MITH1_1","2r0l","Homo sapiens","HEPATOCYTE GROWTH FACTOR ACTIVATOR","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None","0.46A","1etrH-2r0lA:34.7","1etrH-2r0lA:32.59"],["1ETR_H_MITH1_1","2r2w","Homo sapiens","PLASMINOGEN ACTIVATOR, UROKINASE","PF00089(Trypsin)",6,"HIS U  57;ASP U 189;VAL U 213;TRP U 215;GLY U 216;GLY U 226","4PG U 300 (-3.9A);4PG U 300 (-2.8A);None;None;4PG U 300 (-3.3A);4PG U 300 (-3.2A)","0.42A","1etrH-2r2wU:35.1","1etrH-2r2wU:31.75"],["1ETR_H_MITH1_1","2r2w","Homo sapiens","PLASMINOGEN ACTIVATOR, UROKINASE","PF00089(Trypsin)",6,"HIS U  57;SER U 195;VAL U 213;TRP U 215;GLY U 216;GLY U 226","4PG U 300 (-3.9A);4PG U 300 (-3.5A);None;None;4PG U 300 (-3.3A);4PG U 300 (-3.2A)","0.51A","1etrH-2r2wU:35.1","1etrH-2r2wU:31.75"],["1ETR_H_MITH1_1","2wpm","Homo sapiens","COAGULATION FACTOR IXA HEAVY CHAIN","PF00089(Trypsin)",6,"HIS S  57;ASP S 189;SER S 195;TRP S 215;GLY S 216;GLY S 226","None","0.72A","1etrH-2wpmS:34.5","1etrH-2wpmS:39.15"],["1ETR_H_MITH1_1","2zec","Homo sapiens","TRYPTASE BETA 2","PF00089(Trypsin)",7,"HIS A  59;ASP A 203;SER A 209;VAL A 227;TRP A 229;GLY A 230;GLY A 240","None;11N A   1 (-2.6A);11N A   1 (-3.3A);None;None;11N A   1 (-3.9A);11N A   1 (-3.6A)","0.55A","1etrH-2zecA:33.3","1etrH-2zecA:36.57"],["1ETR_H_MITH1_1","3beu","Streptomyces griseus","TRYPSIN","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","SO4 A 246 ( 3.8A);BEN A 247 (-3.0A);SO4 A 246 ( 2.5A);None;None;BEN A 247 (-3.7A);BEN A 247 (-3.5A)","0.49A","1etrH-3beuA:31.3","1etrH-3beuA:35.27"],["1ETR_H_MITH1_1","3f6u","Homo sapiens","VITAMIN K-DEPENDENT PROTEIN C HEAVY CHAIN","PF00089(Trypsin)",7,"ASP H 189;GLU H 192;SER H 195;VAL H 213;TRP H 215;GLY H 216;GLY H 226","0G6 H   1 (-2.8A);0G6 H   1 ( 4.0A);0G6 H   1 (-1.8A);None;0G6 H   1 (-4.1A);0G6 H   1 (-3.8A);0G6 H   1 ( 3.9A)","0.66A","1etrH-3f6uH:35.2","1etrH-3f6uH:41.15"],["1ETR_H_MITH1_1","3f6u","Homo sapiens","VITAMIN K-DEPENDENT PROTEIN C HEAVY CHAIN","PF00089(Trypsin)",7,"HIS H  57;ASP H 189;SER H 195;VAL H 213;TRP H 215;GLY H 216;GLY H 226","0G6 H   1 (-3.2A);0G6 H   1 (-2.8A);0G6 H   1 (-1.8A);None;0G6 H   1 (-4.1A);0G6 H   1 (-3.8A);0G6 H   1 ( 3.9A)","0.67A","1etrH-3f6uH:35.2","1etrH-3f6uH:41.15"],["1ETR_H_MITH1_1","3gov","Homo sapiens","MASP-1","PF00089(Trypsin)",7,"HIS B 490;ASP B 640;SER B 646;VAL B 666;TRP B 668;GLY B 669;GLY B 679","None","0.55A","1etrH-3govB:36.0","1etrH-3govB:36.13"],["1ETR_H_MITH1_1","3gym","Homo sapiens","PROSTASIN","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None","0.66A","1etrH-3gymA:33.8","1etrH-3gymA:37.32"],["1ETR_H_MITH1_1","3nxp","Homo sapiens","PRETHROMBIN-1","PF00051(Kringle);PF00089(Trypsin);PF09396(Thrombin_light)",5,"HIS A 457;TYR A 460;LEU A 499;VAL A 613;GLY A 626","None","0.57A","1etrH-3nxpA:29.6","1etrH-3nxpA:87.26"],["1ETR_H_MITH1_1","3r3g","Homo sapiens","THROMBIN HEAVY CHAIN","PF00089(Trypsin)",10,"HIS B  57;TYR B  60;LEU B  99;ASP B 189;GLU B 192;SER B 195;VAL B 213;TRP B 215;GLY B 216;GLY B 226","None","0.78A","1etrH-3r3gB:43.5","1etrH-3r3gB:88.03"],["1ETR_H_MITH1_1","3r3g","Homo sapiens","THROMBIN HEAVY CHAIN","PF00089(Trypsin)",6,"TYR B  60;TRP B  60;LEU B  99;ASP B 189;GLY B 216;GLY B 226","None","0.79A","1etrH-3r3gB:43.5","1etrH-3r3gB:88.03"],["1ETR_H_MITH1_1","3rip","Homo sapiens","GAMMA-TUBULIN COMPLEX COMPONENT 4","PF04130(Spc97_Spc98)",5,"LEU A 197;GLU A 304;SER A 188;GLY A 194;GLY A 280","None","0.85A","1etrH-3ripA:undetectable","1etrH-3ripA:17.29"],["1ETR_H_MITH1_1","3s69","Gloydius saxatilis","THROMBIN-LIKE ENZYME DEFIBRASE","PF00089(Trypsin)",6,"HIS A  56;ASP A 189;SER A 195;VAL A 209;GLY A 212;GLY A 223","None","0.53A","1etrH-3s69A:31.3","1etrH-3s69A:32.20"],["1ETR_H_MITH1_1","3w94","Oryzias latipes","ENTEROPEPTIDASE-1","PF00089(Trypsin)",5,"HIS A 836;ASP A 973;SER A 979;GLY A1000;GLY A1010","None","0.54A","1etrH-3w94A:36.1","1etrH-3w94A:35.25"],["1ETR_H_MITH1_1","4bxw","Pseudonaja textilis","FACTOR XA","PF00089(Trypsin);PF14670(FXa_inhibition)",6,"HIS A 211;ASP A 356;SER A 362;VAL A 380;GLY A 383;GLY A 393","0GJ A1411 (-2.8A);0GJ A1411 (-2.7A);0GJ A1411 (-1.4A);None;0GJ A1411 (-3.7A);0GJ A1411 (-3.3A)","0.69A","1etrH-4bxwA:32.9","1etrH-4bxwA:38.83"],["1ETR_H_MITH1_1","4dgj","Homo sapiens","ENTEROPEPTIDASE CATALYTIC LIGHT CHAIN","PF00089(Trypsin)",5,"HIS A  41;ASP A 181;SER A 187;GLY A 208;GLY A 218","None","0.72A","1etrH-4dgjA:36.3","1etrH-4dgjA:35.52"],["1ETR_H_MITH1_1","4dzt","Thermus aquaticus","AQUALYSIN-1","PF00082(Peptidase_S8)",5,"TYR A 209;TRP A 208;VAL A  96;GLY A 101;GLY A 103","None","0.93A","1etrH-4dztA:undetectable","1etrH-4dztA:18.91"],["1ETR_H_MITH1_1","4e7n","Gloydius halys","SNAKE-VENOM THROMBIN-LIKE ENZYME","PF00089(Trypsin)",5,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216","None","0.62A","1etrH-4e7nA:31.0","1etrH-4e7nA:33.33"],["1ETR_H_MITH1_1","4fxg","Homo sapiens","MANNAN-BINDING LECTIN SERINE PROTEASE 2 B CHAIN","PF00089(Trypsin)",6,"HIS H 483;ASP H 627;VAL H 653;TRP H 655;GLY H 656;GLY H 667","None","0.55A","1etrH-4fxgH:34.7","1etrH-4fxgH:34.47"],["1ETR_H_MITH1_1","4gso","Bothrops jararacussu","THROMBIN-LIKE ENZYME BJUSSUSP-1","PF00089(Trypsin)",5,"ASP A 172;SER A 178;VAL A 192;GLY A 195;GLY A 206","None","0.62A","1etrH-4gsoA:undetectable","1etrH-4gsoA:34.46"],["1ETR_H_MITH1_1","4h4f","Homo sapiens","CHYMOTRYPSIN-C","PF00089(Trypsin)",5,"HIS A  57;LEU A  99;SER A 195;VAL A 213;GLY A 216","None","0.59A","1etrH-4h4fA:34.4","1etrH-4h4fA:34.98"],["1ETR_H_MITH1_1","4hzh","Homo sapiens","PROTHROMBIN","PF00051(Kringle);PF00089(Trypsin);PF09396(Thrombin_light)",6,"HIS A 363;TYR A 367;TRP A 370;LEU A 416;VAL A 545;GLY A 558","None","0.93A","1etrH-4hzhA:29.8","1etrH-4hzhA:86.87"],["1ETR_H_MITH1_1","4hzh","Homo sapiens","PROTHROMBIN","PF00051(Kringle);PF00089(Trypsin);PF09396(Thrombin_light)",6,"HIS A 363;TYR A 367;TRP A 370;VAL A 545;GLY A 548;GLY A 558","None","1.29A","1etrH-4hzhA:29.8","1etrH-4hzhA:86.87"],["1ETR_H_MITH1_1","4iw4","Homo sapiens","MANNAN-BINDING LECTIN SERINE PROTEASE 3","PF00089(Trypsin)",7,"HIS E 478;ASP E 639;SER E 645;VAL E 665;TRP E 667;GLY E 668;GLY E 680","None","0.70A","1etrH-4iw4E:32.7","1etrH-4iw4E:35.52"],["1ETR_H_MITH1_1","4k8y","Homo sapiens","KALLIKREIN-4","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;VAL A 213;GLY A 216;GLY A 226","None","0.57A","1etrH-4k8yA:32.5","1etrH-4k8yA:32.32"],["1ETR_H_MITH1_1","4k8y","Homo sapiens","KALLIKREIN-4","PF00089(Trypsin)",6,"LEU A  99;ASP A 189;SER A 195;VAL A 213;GLY A 216;GLY A 226","None","0.86A","1etrH-4k8yA:32.5","1etrH-4k8yA:32.32"],["1ETR_H_MITH1_1","4kkd","Homo sapiens","MANNAN-BINDING LECTIN SERINE PROTEASE 1","PF00084(Sushi);PF00089(Trypsin)",5,"HIS A 497;VAL A 684;TRP A 686;GLY A 687;GLY A 699","None","0.54A","1etrH-4kkdA:29.5","1etrH-4kkdA:24.53"],["1ETR_H_MITH1_1","4lk4","Vibrio cholerae","VESB PROTEASE","PF00089(Trypsin)",6,"HIS A  78;LEU A 122;VAL A 237;TRP A 239;GLY A 240;GLY A 251","None","0.64A","1etrH-4lk4A:27.3","1etrH-4lk4A:27.81"],["1ETR_H_MITH1_1","4m7g","Saccharopolyspora erythraea","TRYPSIN-LIKE PROTEASE","PF00089(Trypsin)",6,"HIS A  42;ASP A 173;SER A 179;TRP A 195;GLY A 196;GLY A 206","None","0.43A","1etrH-4m7gA:32.3","1etrH-4m7gA:33.58"],["1ETR_H_MITH1_1","4nff","Homo sapiens","KALLIKREIN-2","PF00089(Trypsin)",5,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216","0G6 A 301 (-2.7A);0G6 A 301 (-3.0A);0G6 A 301 (-1.4A);0G6 A 301 (-3.7A);0G6 A 301 (-3.4A)","0.82A","1etrH-4nffA:33.4","1etrH-4nffA:34.07"],["1ETR_H_MITH1_1","4r0i","Homo sapiens","SUPPRESSOR OF TUMORIGENICITY 14 PROTEIN","PF00089(Trypsin)",7,"HIS A  57;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","3KM A 900 ( 4.4A);3KM A 900 (-2.9A);3KM A 900 (-3.6A);None;None;3KM A 900 (-3.4A);3KM A 900 (-3.2A)","0.50A","1etrH-4r0iA:36.1","1etrH-4r0iA:35.88"],["1ETR_H_MITH1_1","4wwy","Homo sapiens","TRYPSIN-1","PF00089(Trypsin)",8,"HIS A  57;LEU A  99;ASP A 189;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None","0.70A","1etrH-4wwyA:33.9","1etrH-4wwyA:36.68"],["1ETR_H_MITH1_1","4ylq","Homo sapiens","COAGULATION FACTOR VII","PF00089(Trypsin)",7,"HIS H  57;ASP H 189;SER H 195;VAL H 213;TRP H 215;GLY H 216;GLY H 226","0Z7 H 501 (-2.6A);0Z7 H 501 (-2.3A);0Z7 H 501 (-1.4A);0Z7 H 501 ( 4.7A);TMA H 508 ( 3.9A);0Z7 H 501 (-3.4A);0Z7 H 501 (-3.0A)","0.63A","1etrH-4ylqH:34.5","1etrH-4ylqH:36.64"],["1ETR_H_MITH1_1","5brr","Homo sapiens","TISSUE-TYPE PLASMINOGEN ACTIVATOR","PF00089(Trypsin)",5,"HIS E  57;ASP E 189;TRP E 215;GLY E 216;GLY E 226","None","0.50A","1etrH-5brrE:34.9","1etrH-5brrE:32.35"],["1ETR_H_MITH1_1","5eod","Homo sapiens","COAGULATION FACTOR XI","PF00024(PAN_1);PF00089(Trypsin)",5,"HIS A 413;SER A 557;TRP A 577;GLY A 578;GLY A 588","None","0.80A","1etrH-5eodA:27.5","1etrH-5eodA:17.17"],["1ETR_H_MITH1_1","5f8z","Homo sapiens","PLASMA KALLIKREIN LIGHT CHAIN","PF00089(Trypsin)",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None","0.47A","1etrH-5f8zA:34.7","1etrH-5f8zA:39.62"],["1ETR_H_MITH1_1","5gvt","Mus musculus","PLASMA KALLIKREIN","no annotation",5,"HIS A  57;ASP A 189;SER A 195;GLY A 216;GLY A 226","None","0.65A","1etrH-5gvtA:34.6","1etrH-5gvtA:18.73"],["1ETR_H_MITH1_1","5ms3","Homo sapiens","KALLIKREIN-8","no annotation",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None","0.58A","1etrH-5ms3A:32.9","1etrH-5ms3A:15.27"],["1ETR_H_MITH1_1","5n1q","Methanothermococcus thermolithotrophicus","METHYL-COENZYME M REDUCTASE III FROM METHANOTHERMOCOCCUS THERMOLITHOTROPHICUS SUBUNIT BETA","PF02241(MCR_beta);PF02783(MCR_beta_N)",5,"HIS B 199;TYR B 200;LEU B 178;ASP B 169;GLY B 180","None","0.93A","1etrH-5n1qB:undetectable","1etrH-5n1qB:21.22"],["1ETR_H_MITH1_1","5n28","Methanotorris formicicus","METHYL-COENZYME M REDUCTASE, BETA SUBUNIT","PF02241(MCR_beta);PF02783(MCR_beta_N)",5,"HIS B 199;TYR B 200;LEU B 178;ASP B 169;GLY B 180","None","0.88A","1etrH-5n28B:undetectable","1etrH-5n28B:22.60"],["1ETR_H_MITH1_1","5o32","Homo sapiens","COMPLEMENT FACTOR I","PF00089(Trypsin)",5,"ASP I 519;VAL I 544;TRP I 546;GLY I 547;GLY I 557","None","0.86A","1etrH-5o32I:31.0","1etrH-5o32I:34.32"],["1ETR_H_MITH1_1","5o32","Homo sapiens","COMPLEMENT FACTOR I","PF00089(Trypsin)",5,"HIS I 380;VAL I 544;TRP I 546;GLY I 547;GLY I 557","None","0.61A","1etrH-5o32I:31.0","1etrH-5o32I:34.32"],["1ETR_H_MITH1_1","5to3","Homo sapiens","PROTHROMBIN,THROMBOMODULIN","PF00089(Trypsin);PF09064(Tme5_EGF_like)",8,"HIS B  58;TYR B  62;LEU B 111;ASP B 214;SER B 220;VAL B 240;GLY B 243;GLY B 253","0G6 B 501 (-2.5A);0G6 B 501 (-3.7A);0G6 B 501 ( 3.8A);0G6 B 501 (-2.9A);0G6 B 501 (-1.3A);None;0G6 B 501 (-3.7A);0G6 B 501 (-3.6A)","0.60A","1etrH-5to3B:44.1","1etrH-5to3B:79.51"],["1ETR_H_MITH1_1","5to3","Homo sapiens","PROTHROMBIN,THROMBOMODULIN","PF00089(Trypsin);PF09064(Tme5_EGF_like)",6,"TYR B  62;TRP B  65;LEU B 111;ASP B 214;GLY B 243;GLY B 253","0G6 B 501 (-3.7A);0G6 B 501 (-4.8A);0G6 B 501 ( 3.8A);0G6 B 501 (-2.9A);0G6 B 501 (-3.7A);0G6 B 501 (-3.6A)","0.73A","1etrH-5to3B:44.1","1etrH-5to3B:79.51"],["1ETR_H_MITH1_1","5ubm","Homo sapiens","COMPLEMENT C1S SUBCOMPONENT","no annotation",7,"HIS A 475;ASP A 626;SER A 632;VAL A 653;TRP A 655;GLY A 656;GLY A 663","None","0.71A","1etrH-5ubmA:31.3","1etrH-5ubmA:34.93"],["1ETR_H_MITH1_1","5xrf","Deinagkistrodon acutus","SNAKE VENOM SERINE PROTEASE DA-36","no annotation",6,"HIS A  67;ASP A 200;SER A 206;VAL A 220;GLY A 223;GLY A 234","None","0.67A","1etrH-5xrfA:29.7","1etrH-5xrfA:13.87"],["1ETR_H_MITH1_1","5zfh","Mus musculus","KALLIKREIN-7","no annotation",6,"HIS A  57;SER A 195;VAL A 213;TRP A 215;GLY A 216;GLY A 226","None","0.47A","1etrH-5zfhA:32.8","1etrH-5zfhA:17.77"],["1ETR_H_MITH1_1","6b74","Homo sapiens","COAGULATION FACTOR XII","no annotation",6,"HIS B  57;ASP B 189;SER B 195;TRP B 215;GLY B 216;GLY B 226","SO4 B 304 (-3.8A);BEN B 301 (-2.7A);SO4 B 304 ( 2.5A);None;BEN B 301 (-3.3A);BEN B 301 (-3.1A)","0.58A","1etrH-6b74B:34.4","1etrH-6b74B:15.66"]]